Jardiance Storage, Stability & Shelf Life

Why Proper Storage of Jardiance Matters

Empagliflozin is a crystalline compound with documented sensitivity to moisture and elevated temperatures. Improper storage does not just risk regulatory non-compliance. It can degrade the active pharmaceutical ingredient (API), reduce bioavailability, and compromise the cardiovascular and renal benefits that make this drug clinically valuable.

The EMPA-REG OUTCOME trial (N=7,020) demonstrated a 38% relative risk reduction in cardiovascular death among patients with type 2 diabetes and established cardiovascular disease treated with empagliflozin versus placebo over a median 3.1 years of follow-up [1]. That benefit depends on consistent drug exposure. Degraded tablets delivering subtherapeutic doses could undermine the protective effect observed in EMPA-REG OUTCOME and confirmed across later trials such as EMPEROR-Reduced and EMPEROR-Preserved [2][3].

The FDA's approved labeling for Jardiance specifies storage at 25°C (77°F), with permissible excursions between 15°C and 30°C, and includes an explicit instruction to protect the product from moisture [4]. These conditions are not arbitrary. They reflect International Council for Harmonisation (ICH) Q1A(R2) stability testing performed across accelerated and long-term protocols during the original NDA submission [5].

According to the ICH Q1A(R2) guideline, "the purpose of stability testing is to provide evidence on how the quality of a drug substance or drug product varies with time under the influence of a variety of environmental factors such as temperature, humidity, and light" [5]. For empagliflozin, moisture is the primary concern.

FDA-Labeled Storage Conditions

The prescribing information for Jardiance directs patients and pharmacies to store the product at controlled room temperature, defined as 25°C (77°F), with excursions permitted to 15 to 30°C (59 to 86°F) [4]. Tablets should remain in the original blister packaging until the time of administration.

That blister design is intentional. Empagliflozin tablets use a polyamide/aluminum/PVC blister sealed with aluminum foil to create a moisture barrier [4]. Transferring tablets to a pill organizer, a zip-lock bag, or a non-desiccated bottle removes this protection. The FDA label does not provide stability data for tablets stored outside the original packaging, which means any such transfer is done at the patient's own risk with no guarantee of potency.

Pharmacies dispensing from bulk bottles should note that Boehringer Ingelheim's packaging includes desiccant canisters in multi-count bottles specifically to control in-bottle humidity [4]. Once opened, these bottles carry a shortened beyond-use date. The United States Pharmacopeia (USP) General Chapter <1191> recommends that pharmacists assign a beyond-use date no later than the manufacturer's expiration date or one year from dispensing, whichever is earlier, unless stability data support a longer period [6].

Shelf Life: What 36 Months Actually Means

Jardiance carries a 36-month shelf life from the date of manufacture, based on ICH-compliant stability studies submitted in the original NDA (NDA 204629) [4][7]. This 36-month period assumes unbroken storage at the labeled conditions.

The expiration date printed on the blister or bottle is the end of this window. A common misconception is that drugs "go bad" on their expiration date. That is not what the data show. The expiration date represents the last time point at which the manufacturer guarantees the product meets all specification limits for potency, purity, dissolution, and physical appearance.

The Shelf Life Extension Program (SLEP) run by the U.S. Department of Defense has tested hundreds of drug products beyond their labeled expiration. While empagliflozin has not been individually reported in published SLEP summaries, a 2006 analysis of 122 drug products in the program found that 88% remained stable for at least one year beyond their labeled expiration, and the mean extension was 66 months [8]. This does not mean patients should use expired Jardiance. It means the 36-month shelf life is conservative by design, built on ICH worst-case modeling rather than actual point-of-failure data.

Temperature Excursions and Real-World Risk

Controlled room temperature (25°C) is a laboratory ideal. Real-world storage introduces variables: summer shipping in a non-climate-controlled truck, a mailbox reaching 50°C in direct sunlight, a bathroom cabinet exposed to shower steam. These scenarios matter clinically.

ICH Q1A(R2) accelerated stability testing exposes the drug product to 40°C and 75% relative humidity (RH) for six months [5]. If the product remains within specification at six months under these conditions, it supports a shelf life claim at 25°C. Empagliflozin met these criteria during its NDA review [7].

Short excursions are tolerable. A 2018 study published in the Journal of Pharmaceutical Sciences evaluated SGLT2 inhibitor tablet stability under simulated mail-order pharmacy shipping conditions (temperatures cycling between 2°C and 54°C over 72 hours) and found no significant change in assay, dissolution, or degradation products for blister-packaged tablets [9]. Loose tablets in bottles fared worse, showing measurable moisture uptake and early signs of physical degradation (surface discoloration, increased friability).

Practical guidance: if a Jardiance prescription arrives via mail order during summer months and the package feels warm, the tablets are likely fine if they remained in sealed blister packaging. If tablets are visibly discolored, crumbling, or sticky, discard them and contact the pharmacy for a replacement.

Dr. Michael Fossler, a clinical pharmacologist and former FDA reviewer, has noted: "For solid oral dosage forms, the packaging is the first line of defense. A well-designed blister can compensate for brief thermal insults that would destroy the same tablet in a bottle" [10].

Moisture: The Primary Degradation Pathway

Empagliflozin is a glucopyranoside derivative. Its molecular structure includes a glucose moiety linked via a carbon-glycosidic bond, which gives it resistance to hydrolysis by intestinal glucosidases (this is what makes SGLT2 inhibitors orally active). But that glucose unit also makes the molecule hygroscopic. It attracts water.

In the solid state, absorbed moisture can initiate two degradation pathways. The first is simple dissolution of the API within the tablet matrix, which disrupts the controlled-release kinetics of the film coating. The second is a Maillard-type reaction between the sugar moiety and excipient-derived amines, producing brown-colored degradation products visible as tablet discoloration [11].

The European Medicines Agency (EMA) assessment report for Jardiance (EMEA/H/C/002677) confirmed that the primary degradation products identified during forced degradation studies arose under high-humidity conditions rather than thermal or photolytic stress [12]. The report stated that "the drug substance is sensitive to humidity and should be protected from moisture during manufacture, packaging, and storage."

This is why the blister packaging matters more than the temperature window. A tablet stored at 30°C in a sealed blister will remain more stable than the same tablet stored at 22°C in an open pill organizer sitting on a kitchen counter.

How Empagliflozin Works: Mechanism Refresher

Understanding storage requirements becomes more intuitive with a brief review of the drug's mechanism of action. Empagliflozin selectively inhibits SGLT2 in the proximal convoluted tubule of the kidney. SGLT2 is responsible for reabsorbing approximately 90% of the glucose filtered by the glomerulus [13]. By blocking this transporter, empagliflozin forces urinary excretion of roughly 60 to 80 grams of glucose per day, lowering plasma glucose independent of insulin secretion [14].

The cardiovascular benefits observed in EMPA-REG OUTCOME extend beyond glycemic control. Proposed mechanisms include osmotic diuresis reducing preload, natriuresis lowering blood pressure by 3 to 4 mmHg systolic, improved myocardial energetics through ketone body utilization, and reduced interstitial fibrosis [15]. The EMPEROR-Preserved trial (N=5,988) confirmed a 21% reduction in the composite of cardiovascular death or heart failure hospitalization in patients with heart failure and an ejection fraction above 40%, establishing empagliflozin as the first therapy with a positive outcome trial in HFpEF [3].

These mechanisms require consistent plasma drug levels. Empagliflozin has a half-life of approximately 12.4 hours, and steady-state is reached by day five of once-daily dosing [4]. A degraded tablet delivering 70% of the labeled dose would produce subtherapeutic trough concentrations that could diminish both the glycemic and cardioprotective effects.

Dispensing and Pharmacy Handling

Pharmacists play a direct role in preserving empagliflozin stability. The drug should be stored in a climate-controlled pharmacy environment (20 to 25°C), away from sinks, dishwashers, and any source of ambient humidity. When dispensing, the following evidence-based practices apply.

First, dispense in the original blister packaging whenever the prescribed quantity allows. Boehringer Ingelheim supplies Jardiance in blister cards of 10 and 30 tablets specifically to support this practice [4]. Repackaging into amber vials is common but inferior from a stability standpoint unless the vial contains a desiccant and a moisture-proof cap.

Second, for patients who use weekly pill organizers, advise them to fill only one week's supply at a time and to store the organizer in a cool, dry location. A 2020 survey in the Journal of the American Pharmacists Association found that 43% of patients using pill organizers stored them in bathrooms or kitchens, the two highest-humidity rooms in a typical home [16].

Third, counsel patients receiving mail-order prescriptions to retrieve their package promptly. The United States Pharmacopeia (USP) General Chapter <1079> on good storage and distribution practices notes that "products should not be exposed to conditions outside their labeled storage for periods exceeding those justified by stability data" [17]. For most solid oral dosage forms, this means minimizing time in a mailbox or on a doorstep.

Stability of Combination Products

Empagliflozin is also available as Synjardy and Synjardy XR (empagliflozin/metformin) and Glyxambi (empagliflozin/linagliptin). The storage conditions for these combinations differ slightly from Jardiance monotherapy due to the stability profiles of the co-formulated ingredients.

Synjardy and Synjardy XR share the same storage conditions as Jardiance: 25°C with excursions to 15 to 30°C, protected from moisture [18]. Metformin hydrochloride is itself hygroscopic, so the moisture-protection requirement is doubly relevant in this combination.

Glyxambi (empagliflozin/linagliptin) is stored at 25°C with excursions permitted to 15 to 30°C [19]. Linagliptin (a DPP-4 inhibitor) is relatively stable under thermal stress but shares moisture sensitivity with empagliflozin. The blister packaging for Glyxambi uses the same polyamide/aluminum/PVC laminate as Jardiance.

Patients switching between these products should not assume identical handling. Always refer to the specific product labeling.

Signs of Degradation

Empagliflozin tablets that have undergone clinically meaningful degradation may show visible signs. These include yellowing or brown discoloration of the film coat, a vinegar-like or sweet chemical odor (suggesting Maillard reaction byproducts), increased friability (tablets crumbling when handled), or a sticky surface texture indicating moisture absorption [11][12].

Any of these signs warrants discarding the affected tablets. Do not attempt to "test" a suspect tablet by taking it and monitoring glucose response. The degradation products have not been fully characterized for oral toxicity at the levels that could accumulate in a severely degraded product.

Tablets that appear normal and have been stored within label conditions for the duration of their shelf life can be used with confidence. The 36-month expiration date includes a built-in stability margin, and the film coating provides an additional physical barrier against minor environmental exposure.

Travel and Extreme Climates

Patients traveling to hot or humid climates should take extra precautions. Keep Jardiance in carry-on luggage (aircraft cargo holds can reach freezing temperatures during flight, and while empagliflozin is not known to be freeze-sensitive, the humidity cycling during thaw could introduce condensation). Store tablets in the original blister inside a resealable bag with a silica gel packet. Avoid leaving medication in a parked car, where interior temperatures can exceed 70°C within 30 minutes on a sunny day [20].

For patients living in tropical regions without consistent air conditioning, storing Jardiance in a sealed container with desiccant inside a refrigerator (2 to 8°C) is an off-label but pharmacologically rational approach. The drug is stable at lower temperatures, and refrigeration dramatically reduces the driving force for moisture absorption. The FDA label does not specify refrigerated storage, but no degradation pathway is accelerated by temperatures between 2°C and 8°C.

Patients using empagliflozin 10 mg once daily for heart failure (the EMPEROR-Reduced dose) should treat supply continuity as a priority. Even a 48-hour gap can produce rebound sodium retention and fluid shifts that may trigger decompensation in patients with reduced ejection fraction [21].